We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » HHS OIG Subpoenas Gilead Over Ranexa Marketing
HHS OIG Subpoenas Gilead Over Ranexa Marketing
August 21, 2009
Gilead Sciences has received a subpoena from the HHS Office of Inspector General (OIG) requesting documents regarding the development, marketing and sales of its chronic angina drug Ranexa.